Please assess the completion status of the following clinical trial:

Trial Title: A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persistent asthma for at least 1-year~* Must use a daily asthma controller medication for at least 4 weeks prior to randomization, including an inhaled corticosteroid (ICS) with or without a long-acting beta agonist (LABA) or other adjunctive asthma therapy OR be using a leukotriene receptor antagonist (LTRA), xanthine or short acting beta agonist (SABA) as a monotherapy.~* Must be able to discontinue current asthma medication~* Must have a history of at least one asthma exacerbation in previous 4 to 52 weeks~Exclusion Criteria:~* Unstable asthma~* Taking high dose ICS with or without other adjunctive therapy who have an Asthma Control Questionnaire 6 (ACQ6) total score ≥ 1.5~* Taking LTRA, xanthine or SABA monotherapy with an ACQ-6 total score \< 1.5 (controlled)~* Chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), or other significant, non-asthmatic, lung disease~* Clinically significant abnormality, illness or disorder of any body or organ system~* Significant underlying cardiovascular condition which may contraindicate use of a beta-agonist.~* History of smoking greater than 10-pack years~* Had an asthma exacerbation within 4 weeks of the Baseline Visit~* Had more than 4 asthma exacerbations or 2 hospitalizations within 52 weeks of the randomization visit~* Known or suspected hypersensitivity or intolerance to corticosteroids, beta-2 agonists, or any of the (inactive ingredients) excipients present in the medications used in this study~* Require the use of chronic systemic steroids, omalizumab, or other monoclonal or polyclonal antibodies~* Requires the use of beta-blockers~* History of life-threatening asthma, including an asthma episode that required intubation and/or was associated with hypercapnia requiring noninvasive ventilatory support~* Lactating, pregnant, or plans to become pregnant during the course of the trial

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone Furoate/Formoterol MDI BID (Type: EXPERIMENTAL): MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
- Mometasone Furoate MDI BID (Type: ACTIVE_COMPARATOR): MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)

Based on this trial design, predict the completion outcome and termination type (if applicable).